Additional file 1 of Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy

Additional file 1: Figure S1. CLT suppressed UUO-induced renal fibrosis. Figure S2. Representative H&E-stained images of heart, liver, spleen, lung and brain on day 14 after treatment. Figure S3. (A) SDS-PAGE analysis of K3-HBc or HBc-183. (B) Western blot analysis of HBc-183 or K3-HBc with antibody against HBc. Figure S4. Zeta potential of ultra-small CLT nanodots. Figure S5. K3-HBc NCs were administered to the mice in UUO + K3-HBc NCs group by tail vein injection at a dosage of 9.49 mg/kg every other day starting immediately after UUO operation. Figure S6. Anti-EMT effects of CLT orK3-HBc/CLT in vitro. Serum-starved HK-2 cells were incubated with CLT or K3-HBc/CLT (500 nM) for 1 h and then stimulated with TGF-β1 (5 ngmL-1) for 48h. Figure S7. Representative H&E stained images of the organs harvested from the mice after various treatments. Figure S8. Blood biochemistry analyses of the mice after treatment with CLT or K3-HBc/CLTfor 14 days. Figure S9. (A) Blood biochemistry analyses of the healthymice after treatment with K3-HBc for 14 days. The results showed mean and standard deviation of AST, ALT, BUN, CREA, LDH-L, TBiL (n = 3). (B) Representative H&E stained images of the organs harvested from the mice after treatment with K3-HBc for 14 days. Scale bar=100 μm. Figure S10. Serum cytokine analysis in mice. Figure S11. mRNA levels of (A) Cdknla, (B) GADD45, (C) Rprm, (D) Sfn, and (E) Cdk4 were measured by qPCR in obstructed kidney from the mice treated with 0.9%NaCl, CLT, or K3-HBc/CLT for 14 days (n = 3).